Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMoreno, Christophe
dc.contributor.authorSarrazin, Christoph
dc.contributor.authorGschwantler, Michael
dc.contributor.authorFoster, Graham R.
dc.contributor.authorCraxi, Antonio
dc.contributor.authorAsselah, Tarik
dc.contributor.authorButi Ferret, Maria
dc.date.accessioned2021-04-22T07:54:10Z
dc.date.available2021-04-22T07:54:10Z
dc.date.issued2017-01-05
dc.identifier.citationAsselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, et al. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. Grebely J, editor. PLoS One. 2017 Jan 5;12(1):e0168713.
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/11351/5893
dc.descriptionEsdeveniments adversos; Malalties del fetge; Teràpia amb inhibidors de la proteasa
dc.description.sponsorshipThe study described in this manuscript (HPC3014; NCT01846832) was sponsored by Janssen Pharmaceuticals. The funder was involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Editorial support was provided by Ian Grieve (Medical Writer at Zoetic Science, an Ashfield Company, part of UDG Healthcare plc, Macclesfield, UK); this support was funded by Janssen Pharmaceuticals. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
dc.language.isoeng
dc.publisherPublic Library of Science
dc.relation.ispartofseriesPLoS ONE;12(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectFetge - Malalties
dc.subjectMedicaments - Administració
dc.subject.meshLiver Diseases
dc.subject.mesh/drug therapy
dc.titleEfficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1371/journal.pone.0168713
dc.subject.decsenfermedades hepáticas
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0168713
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Asselah T] Hepatology Department, Beaujon Hospital, University of Paris, Paris, France. [Moreno C] CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. [Sarrazin C] Johann Wolfgang Goethe University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany. [Gschwantler M] Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria. [Foster GR] Queen Mary Hospital, University of London, Barts Health, London, United Kingdom. [Craxí A] Sezione di Gastroenterologia & Epatologia, Di.Bi.M.I.S., University of Palermo, Palermo, Italy. [Buti M] Unitat d'Hepatologia, Vall d’Hebron Hospital, Barcelona, Spain. Ciberehd del Instituto Carlos III
dc.identifier.pmid28056030
dc.identifier.wos000391639100010
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple